ZIOPHARM Oncology (NASDAQ:ZIOP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Saturday. The firm currently has a $5.00 price target on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 14.16% from the stock’s current price.
According to Zacks, “ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. “
A number of other research firms have also recently weighed in on ZIOP. BidaskClub raised ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a research report on Thursday. ValuEngine downgraded ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. HC Wainwright reissued a “buy” rating and set a $9.50 target price on shares of ZIOPHARM Oncology in a research note on Tuesday, November 7th. Finally, Raymond James Financial reissued a “hold” rating on shares of ZIOPHARM Oncology in a research note on Monday, December 11th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. ZIOPHARM Oncology currently has an average rating of “Hold” and a consensus target price of $12.67.
ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.13). The company had revenue of $1.60 million for the quarter, compared to analyst estimates of $1.66 million. During the same period in the previous year, the business posted ($0.11) earnings per share. The firm’s revenue was up .0% compared to the same quarter last year. research analysts expect that ZIOPHARM Oncology will post -0.54 EPS for the current fiscal year.
In other ZIOPHARM Oncology news, CEO Laurence James Neil Cooper bought 6,440 shares of the business’s stock in a transaction dated Wednesday, November 8th. The stock was acquired at an average cost of $4.68 per share, with a total value of $30,139.20. Following the purchase, the chief executive officer now owns 1,083,731 shares in the company, valued at approximately $5,071,861.08. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 10.40% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. Steward Partners Investment Advisory LLC purchased a new position in shares of ZIOPHARM Oncology during the 3rd quarter worth approximately $145,000. Belpointe Asset Management LLC purchased a new position in shares of ZIOPHARM Oncology during the 3rd quarter worth approximately $746,000. Ladenburg Thalmann Financial Services Inc. raised its stake in shares of ZIOPHARM Oncology by 127.5% during the 3rd quarter. Ladenburg Thalmann Financial Services Inc. now owns 25,896 shares of the biotechnology company’s stock worth $158,000 after buying an additional 14,513 shares in the last quarter. Chevy Chase Trust Holdings Inc. purchased a new position in shares of ZIOPHARM Oncology during the 3rd quarter worth approximately $104,000. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of ZIOPHARM Oncology by 6.6% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 618,589 shares of the biotechnology company’s stock worth $3,799,000 after buying an additional 38,440 shares in the last quarter. 40.23% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “Zacks Investment Research Upgrades ZIOPHARM Oncology (ZIOP) to Buy” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/06/zacks-investment-research-upgrades-ziopharm-oncology-ziop-to-buy.html.
ZIOPHARM Oncology Company Profile
ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.